A third of companies lack compliance departments

A new pharmaceutical compliance report shows that less than two-thirds of pharma companies have dedicated compliance departments. "There is no doubt in my mind that companies with dedicated compliance departments are better prepared to handle and adapt to these changes," said lead author David Richardson, senior analyst for Cutting Edge Information. Release

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.